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Background: Weak cough may result in the failure of noninvasive positive pressure ventilation
(NPPV) in patients with AECOPD. However, no detailed descriptions have yet been published
for the measurement of cough strength and associated outcomes in AECOPD patients.
Methods: This study prospectively enrolled 261 AECOPD patients who received NPPV. Semi-
quantitative cough strength score (SCSS, ranging from 0 Z weak to 5 Z strong) was recorded
before NPPV. Patients who required intubation were defined as NPPV failures.
Results: NPPV failed in 55 patients (21.1%). Weak cough (SCSS 3, OR Z 8.1), high disease
severity (APACHE II score >19, OR Z 3.8), and malnutrition (total proteins 58 g/L,
ORZ 2.8) were independent risk factors for NPPV failure. Patients with 1, 2, and 3 risk factors
were 4.7, 13.6, and 21.6 times more likely, respectively, to experience NPPV failure compared
with patients with no risk factors. The NPPV failure rates were 80%, 40%, and 10.2% in patients
with SCSS of 0e1, 2e3, and 4e5, respectively (p < 0.001). Compared with NPPV success pa-
tients, NPPV failure patients stayed longer in ICU (10.1  7.9 days vs. 6.5  4.6 days,
p < 0.001), and they had higher ICU costs (V2986  1906 vs. V5680  3,604, p < 0.001), higher
hospital costs (V 6714  7025 vs. V10,399  9,509, p Z 0.009), and higher hospital mortality
(72.7% vs. 4.4%, p < 0.001). Moderate accuracy to distinguish NPPV failure by APACHE II score,of Respiratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Youyi Road 1,
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1802 L. Fan et al.SCSS, and total proteins was evidenced by ROC curves, with areas under the curve of 0.71,
0.78, and 0.67, respectively. A combination of all three factors reached good accuracy, with
an area under the curve of 0.86.
Conclusion: AECOPD patients with weak cough had a high risk of NPPV failure. SCSS, APACHE II
scores, and total proteins were predictors of NPPV failure. Combined, these factors increased
the power to predict NPPV failure.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
The use of noninvasive positive pressure ventilation (NPPV)
has increased dramatically in recent years [1]. Especially in
patients with acute exacerbation of chronic obstructive
pulmonary disease (AECOPD), NPPV has become the first-
line intervention [2], and guidelines strongly recommend
the use of NPPV in patients with AECOPD [3,4]. Although
NPPV reduces the rate of endotracheal intubation, costs of
intensive care unit (ICU) stay, and mortality, the NPPV
failure rate ranges from 7% to 31% in AECOPD patients
[5e8]. Worse, NPPV failure delays intubation, which results
in increased mortality [9e11]. Thus, early identification of
NPPV failure and avoidance of delayed intubation are
important in AECOPD patients.
The cough reflex is an important defense mechanism,
the main function of which is to remove mucus and/or
foreign bodies from the airways by generating a high expi-
ratory flow [12]. Impaired cough increases the risk of
reintubation in patients who passed a spontaneous breath
trial and had their endotracheal tube removed [13,14].
Patients with weak cough were four times more likely to
require reintubation compared to those with moderate to
strong cough [15]. However, the measurement of cough
strength and associated outcomes in AECOPD patients who
required NPPV has not been reported in detail. Thus, we
used the semiquantitative cough strength score (SCSS) to
assess cough strength. Furthermore, we reported SCSS-
associated outcomes in AECOPD patients who required
NPPV.Materials and methods
We performed a prospective observational study in a res-
piratory ICU between October 2012 and May 2014. The
study was approved by our investigational review board
(First Affiliated Hospital of Chongqing Medical University).
Written informed consent was obtained from all patients or
their next of kin.
NPPV was initiated by the attending physicians based on
at least one of the indicators for NPPV as follows: (1) res-
piratory rate more than 25 breaths/min, (2) pH less than
7.35, (3) PaCO2 more than 45 mmHg, (4) PaO2/FiO2 less than
200 mmHg, and (5) vigorous activity of accessory respira-
tory muscles. We enrolled all patients who received NPPV
because of AECOPD. However, we excluded all patients who
required immediate intubation, had on file a do-not-
intubate or do-not-resuscitate order, or were less than 18years of age. Patient demographics were recorded at
admission. The APACHE II score and SCSS were recorded
before NPPV was initiated. If a patient needed intubation
for invasive mechanical ventilation, NPPV was considered
to have failed.Semiquantitative cough strength score
We used SCSS to evaluate the patients’ cough strength [15].
Cough strength was scored as follows: 0 Z no cough on
command, 1Z audible movement of air through mouth but
no audible cough, 2 Z weakly (barely) audible cough,
3 Z clearly audible cough, 4 Z stronger cough, and
5 Z multiple sequential strong coughs.NPPV setting
Patients were ventilated with bi-level positive airway
pressure in S/T mode (BiPAP Vision or Respironics V60).
Expiratory positive airway pressure was initially set at 4 cm
H2O and titrated according to the flow curve to ensure that
expiratory flow reached zero prior to inspiration or dimin-
ished ineffective efforts [16]. FiO2 was set to maintain SpO2
at around 95%. Inspiratory positive airway pressure was
adjusted in increments of 2 cm H2O to obtain a tidal volume
more than 6 mL/kg every 5e6 min, or to the maximum
tolerated level for each patient. A maximum generated
tidal volume of 10 mL/kg was recommended. A face mask
(ZS-MZ-A Face Mask, Shanghai Zhongshan Medical Technol-
ogy Co., Shanghai, China) was used for all patients.
Disconnection from the ventilator for short periods was
allowed for patients to clear secretions, drink water, or eat
food but was not scheduled. All patients were rigorously
monitored at bedside to ensure optimal NPPV use [17]. If
the respiratory failure was reversed, disconnection of NPPV
equipment was performed per hospital protocol [18].Criteria for intubation
A need for intubation was determined by attending physi-
cians if patients presented one major criterion or at least
two minor criteria after initial treatment with NPPV
[8,17,19,20]. Major criteria were: (1) respiratory arrest, (2)
loss of consciousness, (3) hemodynamic instability, (4)
inability to correct dyspnea, and (5) PaO2/FiO2 below
100 mmHg. Minor criteria were: (1) respiratory rate more
than 35 breaths/min, (2) blood pH less than 7.30, (3)
SCSS and associated outcomes in NPPV with AECOPD 1803persistent tachypnea, (4) persistent activation of accessory
respiratory muscles, and (5) PaO2/FiO2 below 200 mmHg.
Data analysis
The data were analyzed with statistical software (SPSS
17.0, SPSS, Chicago, IL, USA). An unpaired Student’s t test
was used to analyze normally distributed continuous vari-
ables, and the chi-squared test was used to analyze cate-
gorical variables. The diagnostic accuracy of NPPV failure
was analyzed by receiver operating characteristic curves.
The optimal cut-off value was chosen by the maximum
Youden index [21]. Variables with p < 0.2 in univariate
analysis and other potentially important biological vari-
ables were analyzed by stepwise multiple logistic regres-
sion analysis. Continuous variables between different
groups (distinguished by SCSS) were analyzed using one-way
analysis of variance. A p value <0.05 was considered
significant.
Results
We enrolled 261 patients in this study. NPPV failed in 55
patients (21.1%). Before NPPV was begun, the failed pa-
tients had higher APACHE II score (21.0  5.6 vs. 17.1  4.1,
p < 0.001), lower SCSS (2.6  1.4 vs. 3.9  0.8, p < 0.001),
and lower total proteins (57.1  7.2 g/L vs. 62.4  8.4 g/L,
p < 0.001) than successful patients (Table 1). APACHE IITable 1 Baseline characteristics of the patients before
NPPV.
NPPV success
N Z 206
NPPV failure
N Z 55
p
Age, years 72.3  9.3 74.3  10.6 0.169
Male/female 143/63 46/9 0.029*
APACHE II score 17.1  4.1 21.0  5.6 <0.001*
GCS 14.8  0.5 13.8  2.5 0.007*
SCSS 3.9  0.8 2.6  1.4 <0.001*
Respiratory rate,
breaths/min
27.8  5.4 29.8  6.3 0.037*
Heart rate, beats/min 108.1  23.6 120.0  27.7 0.002*
Systolic blood
pressure, mmHg
135.3  22.7 135.8  20.8 0.869
Diastolic blood
pressure, mmHg
80.7  13.8 80.8  12.2 0.964
pH 7.35  0.10 7.36  0.10 0.569
PaCO2, mmHg 67.0  22.5 60.4  23.4 0.065
PaO2, mmHg
a 73.4  33.5 69.4  27.5 0.412
PaO2/FiO2 183.4  87.7 154.6  75.0 0.027*
Creatinine, mmol/L 80.6  54.3 90.3  56.8 0.246
Prealbumin, mg/Lb 147.4  67.2 108.6  60.7 0.001*
Albumin, g/L 33.3  5.5 30.1  5.8 <0.001*
Total proteins, g/L 62.4  8.4 57.1  7.2 <0.001*
GCS, Glasgow coma scale; SCSS, semiquantitative cough
strength score.
*p < 0.05 for NPPV success versus NPPV failure patients.
a Some patients received supplemental oxygen.
b Prealbumin measurements were available for 142 patients in
the NPPV success group and 43 in the NPPV failure group.score, SCSS, and total proteins were each independent
predictors of NPPV failure, with odds ratios (ORs) of 1.111
(95% confidence interval [CI]: 1.021e1.209), 0.351 (95% CI:
0.241e0.510), and 0.891 (95% CI: 0.843e0.942), respec-
tively (Table 2).
The optimal cut-off point, as determined by the Youden
index, was APACHE II score >19, SCSS 3, and total pro-
teins 58 g/L (Table 3). The ORs for NPPV failure were,
respectively, 3.8, 8.1, and 2.8 in patients with APACHE II
score >19 vs. 19, SCSS 3 vs. >3, and total proteins 58
vs. >58 g/L (Table 4). The NPPV failure rates were 3.3%,
15.6%, 45%, and 71.4% in patients with 0, 1, 2, and 3 risk
factors, respectively (Fig. 1). Compared to patients with no
risk factors, the relative risks of NPPV failure were 4.7,
13.6, and 21.6 in patients with 1, 2, and 3 risk factors,
respectively. The use of APACHE II score, SCSS, or total
proteins alone to predict NPPV failure had moderate
discriminatory power. When the three tests were com-
bined, good discriminatory power was reached (Table 3 and
Fig. 2).
The NPPV failure patients had longer duration of ICU
stay, higher ICU costs, higher hospital costs, and higher
hospital mortality (Table 5). Patients with SCSS 0e1, 2e3,
and 4e5 had high risk, moderate risk, and low risk of NPPV
failure (80%, 40%, and 10.2%, respectively) (Fig. 3 and
Table 6).Discussion
NPPV is commonly used in AECOPD patients because it im-
proves clinical symptoms and reduces the intubation rate
compared with usual care alone [6e8]. However, a meta-
analysis that included 8 randomized controlled trials re-
ported an average rate of NPPV failure of 13.9% in AECOPD
patients [22]. Notably, these studies only enrolled highly
selected patients. If other patients had been included, the
failure rate would be higher. Because of the high preva-
lence of COPD (range, 7.8%e19.7%) in population aged 40
years or older, this issue deserves attention [23]. In patients
who failed NPPV and subsequently received endotracheal
intubation, the condition was worsened, intubation was
delayed, and mortality was increased [9e11]. Thus, it is
important to select patients who will respond to NPPV. In
our study, we found that APACHE II score, SCSS, and total
proteins, assessed before NPPV, were independent pre-
dictors of NPPV failure in AECOPD patients. This may help
physicians to make treatment decisions.
The APACHE II scoring system was developed by Knaus
and colleagues in 1985 [24]. It has significant sensitivity and
specificity to distinguish the severity of disease in critical
care patients [25,26]. Hence, the NPPV failure rate and
mortality increase with a higher APACHE II score. Phua and
coworkers demonstrated that a high APACHE II score was
associated with NPPV failure in COPD patients (OR, 5.38 per
5 points) [27]. A similar outcome was observed in our study.
APACHE II score had moderate discriminatory power to
predict NPPV failure in AECOPD patients. In patients with
APACHE II score >19, the OR of NPPV failure was 3.8,
compared to patients with an APACHE II score 19.
Cough strength reflects the ability of a person to clear
secretions and foreign bodies from the airways. An
Table 2 Univariate and multivariate analyses of the risk factors associated with NPPV failure.
Variables Unadjusted OR (95% CI) p Adjusted OR (95% CI) p
Age, years 1.024 (0.990e1.059) 0.169 e e
Male/female 2.252 (1.039e4.880) 0.040 e e
APACHE II score 1.200 (1.114e1.291) <0.001 1.111 (1.021e1.209) 0.015
GCS 0.465 (0.300e0.421) 0.001 e e
SCSS 0.364 (0.263e0.503) <0.001 0.351 (0.241e0.510) <0.001
Respiratory rate, breaths/min 1.062 (1.008e1.119) 0.023 e e
Heart rate, beats/min 1.019 (1.007e1.031) 0.002 e e
Systolic blood pressure, mmHg 1.001 (0.988e1.015) 0.868 e e
Diastolic blood pressure, mmHg 1.001 (0.979e1.023) 0.964 e e
pH 2.507 (0.107e58.610) 0.568 e e
PaCO2, mmHg 0.987 (0.973e1.000) 0.059 e e
PaO2, mmHg 0.996 (0.986e1.006) 0.412 e e
PaO2/FiO2 0.995(0.991e0.999) 0.026 e e
Creatinine, mmol/L 0.999 (0.992e1.005) 0.719 e e
Albumin, g/L 1.042 (0.913e1.189) 0.541 e e
Total proteins, g/L 0.845(0.766e0.932) 0.001 0.891 (0.843e0.942) <0.001
OR, odds ratio; CI, confidence interval; GCS, Glasgow coma scale; SCSS, semiquantitative cough strength score.
Table 3 Analysis of APACHE II score, SCSS and total proteins by ROC curves and optimal cut-off values.
Optimal cut-off value Sensitivity (%) Specificity (%) AUC mean  SE AUC 95% CI
APACHE II score >19 56.4 74.8 0.71  0.04 0.65e0.76
SCSS 3 65.3 81.1 0.78  0.03 0.72e0.83
Total proteins, g/L 58 58.2 67.0 0.67  0.04 0.61e0.73
Combinationa e 67.3 87.9 0.86  0.03 0.81e0.90
SCSS, semiquantitative cough strength score; ROC, receiver operating characteristic; AUC, area under the curve; SE, standard error; CI,
confidence interval.
a Combination of APACHE II score, SCSS, and total proteins.
1804 L. Fan et al.impaired cough can lead to airway obstruction and even
apnea in patients with a large volume of sputum. Most
AECOPD patients produce a large volume of purulent
sputum [28]. Zhu and workmates reported that the inability
to clear excessive airway secretions was the most common
reason for NPPV failure in COPD patients, accounting forTable 4 Odds ratio of NPPV failure in APACHE II score,
SCSS and total proteins.
OR (95%CI) p
APACHE II score >19 vs. others 3.8 (2.1e7.1) <0.001
SCSS 3 vs. others 8.1 (4.2e15.6) <0.001
Total proteins 58 g/L vs. others 2.8 (1.5e5.2) 0.001
APACHE II score >19 and
SCSS 3 vs. others
5.9 (2.8e12.4) <0.001
APACHE II score >19 and total
proteins 58 g/L vs. others
5.0 (2.4e10.6) <0.001
SCSS 3 and total proteins
58 g/L vs. others
11.2 (4.8e25.9) <0.001
APACHE II score >19, SCSS
3 and total proteins
58 g/L vs. others
11.2 (3.4e37.4) <0.001
OR, odds ratio; CI, confidence interval; SCSS, semiquantitative
cough strength score.58% of failures [29]. Thus, AECOPD patients with weak
airway protection have a high risk of NPPV failure. How-
ever, to our knowledge, there are few studies reporting on
evaluation methods for cough strength in AECOPD patients
who require NPPV. In our study, we used SCSS to assess
cough strength before initiating NPPV. The measurement of
SCSS was noninvasive and could be performed at bedside.
This assessment of cough is simple and convenient for
clinical practitioners.
In this study, we found that the NPPV failure rates
reached 80% and 40% in patients with SCSS of 0e1 and 2e3,
respectively. Given the high rate of NPPV failure, we sug-
gest that NPPV is inappropriate for AECOPD patients with
SCSS 0e1. In patients with SCSS 2e3, NPPV should be used
with caution. If clinical symptoms are further aggravated,
endotracheal intubation must be carried out. We also found
that patients with a weak cough had low levels of con-
sciousness, as assessed by Glasgow coma scale (Table 6).
This may confound our findings, in that if both conscious-
ness and cough strength improved after NPPV use, this
would indicate that patients’ cough was influenced by
consciousness. If consciousness improved but cough
strength did not, this would indicate that the weak cough
was caused by other factors (e.g. respiratory muscle
weakness).
Prealbumin, albumin, and total protein levels reflect a
patient’s nutritional status. Critically ill patients with low
Figure 1 Intubation rate and relative risk of NPPV failure in patients with different risk factors (the three risk factors were
APACHE II score >19, SCSS 3, and total proteins 58 g/L).
Figure 2 The diagnostic accuracy of NPPV failure was
analyzed by receiver operating characteristic curve. The area
under the curve was 0.71, 0.78, and 0.67 for APACHE II score,
SCSS, and total proteins, respectively. When APACHE II score,
SCSS, and total proteins were combined, diagnostic accuracy
increased to 0.86.
Table 5 Outcomes compared between NPPV success and
NPPV failure patients.
NPPV success
N Z 206
NPPV failure
N Z 55
p
Duration of ICU
stay, days
6.5  4.6 10.1  7.9 <0.001*
Duration of hospital
stay, days
15.9  12.1 17.5  14.0 0.416
ICU costs, V 2986  1906 5680  3604 <0.001*
Hospital costs, V 6714  7025 10,399  9509 0.009*
Hospital mortality 9(4.4%) 40(72.7%) <0.001*
*p < 0.05 for NPPV success versus NPPV failure patients.
SCSS and associated outcomes in NPPV with AECOPD 1805albumin have high mortality rates [30,31]. However, to our
knowledge, no study has yet reported a correlation be-
tween nutritional status and NPPV failure. Our study found
that total protein level was an independent risk factor for
NPPV failure in AECOPD patients. Patients with low total
proteins had a higher risk of NPPV failure (total proteins
58 vs. >58 g/L, OR Z 2.8).
In routine clinical practice, no physicians use only one
factor to manage their patients. However, it is difficult to
assess the appropriate combination of many clinical vari-
ables. In our study, we found that APACHE II score, SCSS,
and total proteins were independent factors in predicting
NPPV failure in AECOPD patients. With each factor consid-
ered alone, the distinguishing power reached moderate
accuracy. When the factors were combined, good dis-
tinguishing power was achieved.
The major limitation of this study was in accurate
assessment of cough strength by SCSS. Because SCSS is a
semiquantitative measurement, accuracy of measurements
is based on the clinicians’ experience. To prevent bias, we
trained clinicians so that maximal homogeneity was
reached before performing the study. Thus, we suggest that
rigorous training is valuable before using the SCSS to
manage NPPV patients. Additionally, measurement of
cough peak flow by flowmeter is quantitative. This may
therefore represent a more objective means to measure
patients’ cough strength. However, because experimental
funding was limited, we chose SCSS, a semiquantitative
measurement that was free of cost. Future studies mightFigure 3 The intubation rate classified by SCSS.
Table 6 Comparisons in patients with different SCSS.
SCSS 0e1
N Z 15
2e3
N Z 60
4e5
N Z 186
p
GCS 12.8  3.5 14.5  0.9 14.9  0.9 <0.001*
Creatinine, mmol/L 90.0  82.3 91.4  77.2 79.2  42.1 0.271
Albumin, g/L 32.7  5.4 31.4  5.2 33.0  5.8 0.133
Total proteins, g/L 61.2  6.6 59.9  8.2 61.7  8.6 0.369
Duration of ICU stay, days 12.4  9.2 7.4  4.9 6.9  5.3 0.001*
Duration of hospital stay, days 24.2  20.6 17.3  12.2 15.3  11.6 0.021*
ICU costs1 4040  3783 4592  3379 3091  1978 0.010*
8382  5,117a 4291  3,180a 3085  1,990a <0.001*
Hospital costs, V 13,951  14,287 8692  6898 6582  6998 0.001*
NPPV failure 12(80%) 24(40%) 19(10.2%) <0.001*
Hospital mortality 10(66.7%) 21(35%) 18(9.7%) <0.001*
SCSS Z semiquantitative cough strength score, GCS Z Glasgow coma scale.
*p <0.05 for analysis in different groups by one-way analysis of variance or chi-squared test.
a Reported ICU costs in survivors.
1806 L. Fan et al.include the quantitative measurement of cough strength if
adequate funds are available.
Conclusion
SCSS was a predictor of NPPV failure in AECOPD patients.
Patients with a weak cough usually had a poorer prognosis.
APACHE II score and total proteins were other predictors of
NPPV failure. Combined, SCSS, APACHE II score, and total
proteins had increased power to predict NPPV failure.
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